CER-001 is well tolerated when administered to humans as single doses up to 45 mg/kg.

CER-001 mobilises cholesterol and increases its elimination via reverse lipid transport.

CER-001 inhibits atherosclerotic plaque progression, providing considerable optimism that it may address the residual risk of cardiovascular events that remains after maximum clinical benefit has been achieved using low-density lipoprotein-cholesterol-lowering therapies.